New 'Smart' immune therapy takes on lupus and arthritis

NCT ID NCT06888960

Recruiting now Disease control Sponsor: CytoCares Inc Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase study is testing a new drug called CC312 in 18 adults with severe autoimmune diseases like lupus and rheumatoid arthritis that haven't improved with standard treatments. CC312 is a type of immune therapy designed to target and destroy faulty B cells, similar to CAR-T therapy. The main goal is to check if it is safe and to find the right dose, with a lower starting dose to reduce the risk of serious side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CC312 (a type of immune cell therapy that targets B cells)
What this could lead to: If it works, this could point toward a new treatment option for people with autoimmune diseases that haven't responded to other therapies.
What could go wrong: This is a very early, small study (only 18 people) focused on safety, not effectiveness. There is a risk of serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune hemolytic anemia autoimmune thrombocytopenic purpura idiopathic inflammatory myopathy myositis disease primary thrombocytopenia Purpura, Thrombocytopenic, Idiopathic rheumatoid arthritis systemic lupus erythematosus systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE HEMOLYTIC ANEMIA IDIOPATHIC INFLAMMATORY MYOPATHY (IIM) PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) RHEUMATOID ARTHRITIS (RA) SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) SYSTEMIC SCLEROSIS (SSC)

Contacts and locations

Locations

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
RECRUITING

Tianjin, China, 300030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.